Company intelligence / Profile preview

Quasuras

San Francisco, California, United States

Ownership: Public · MODD
Development stage: Other

Overview

Quasuras is a biotechnology company focused on developing small molecule therapeutics that modulate the cellular protein quality control machinery. The company specifically targets molecular chaperones, such as Hsp70, to restore protein homeostasis and facilitate the degradation of disease-causing misfolded proteins. Their platform is designed to address high-met-need areas in neurodegeneration, including Alzheimer's and Parkinson's disease, as well as oncology. Founded by leading researchers from UCSF, Quasuras is pioneering a new approach to protein degradation that leverages the cell's natural chaperone systems.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of California, San Francisco

Beyond the preview

Go deeper on Quasuras.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quasuras.

Explore the full profile